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Characterization of a Conserved Structural
Determinant Controlling Protein Kinase
Sensitivity to Selective Inhibitors
one major class of these molecularly targeted agents,
and the first of them, STI571 (Gleevec, imatinib mesylate)
and ZD1839 (Iressa, gefitinib), have already entered the
market [4, 5]. STI571 is a potent inhibitor of the tyrosine
kinases Abl, c-kit, and platelet-derived growth factor
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Semmelweis University was observed in patients with advanced CML. Analysis
Puskin u. 9 of Bcr-Abl from relapsed patients revealed a variety of
Budapest, 1088 amino acid substitutions within the Abl kinase domain,
Hungary and biochemical and biological assays established
these mutations as molecular determinants for STI571
insensitivity [7, 8]. These results raise the critical issue
of whether molecular resistance formation will emergeSummary
as a general drawback inherent to protein kinase-tar-
geted anticancer therapy. For Bcr-Abl, some of the mu-Some protein kinases are known to acquire resistance
tations, such as the Thr-315 to isoleucine substitution,to selective small molecule inhibitors upon mutation
directly interfere with STI571 interaction at the ATP bind-of a conserved threonine at the ATP binding site to a
larger residue. Here, we performed a comprehensive ing pocket, whereas most of them induce structural
mutational analysis of this structural element and de- changes within either the activation loop or the ATP
termined the cellular sensitivities of several disease- phosphate binding loop regions and thereby prevent
relevant tyrosine kinases against various inhibitors. the Abl kinase domain from adapting the closed, inactive
Mutant kinases possessing a larger side chain at the conformation required for the induced fit with STI571
critical site showed resistance to most compounds [8, 9]. Remarkably, these conformation-dependent mech-
tested, such as ZD1839, PP1, AG1296, STI571, and a anisms of drug resistance were recently found to be
pyrido[2,3-d]pyrimidine inhibitor. In contrast, indoli- STI571 specific and did not apply to Bcr-Abl inhibition
nones affected both wild-type and mutant kinases by the pyrido[2,3-d]pyrimidine PD180970 [10]. But this
with similar potencies. Resistant mutants were estab- study further highlighted the significance of the Thr-
lished for pharmacological analysis of PDGF recep- 315 to isoleucine mutation in Bcr-Abl, which conferred
tor-mediated signaling and allowed the generation of resistance to inhibition by both STI571 and PD180970.
a drug-inducible system of cellular Src kinase activity. Interestingly, Thr-315 of Abl corresponds to Thr-106 of
Our data establish a conserved structural determinant p38 and Thr-766 of the epidermal growth factor receptor
of protein kinase sensitivity relevant for both signal (EGFR), and these residues have also been identified as
transduction research and drug development. critical structural determinants for the sensitivities of
these two kinases to the pyridinylimidazole inhibitor
Introduction SB203580 and the 4-anilinoquinazoline PD153035, re-
spectively [11, 12]. The same C to T single nucleotide
Protein kinases control nearly all aspects of cellular sig- change as found in codon 315 of Bcr-Abl from relapsed
nal transmission under both physiological and patho- CML patients replaces Thr-766 of the EGFR by methio-
physiological conditions [1]. In hyperproliferative dis- nine and dramatically desensitizes its tyrosine kinase to
eases such as human cancer, deregulation of protein inhibition by PD153035 [12]. Since PD153035 is related
kinase activity often correlates with disease progression in structure to the recently approved drug ZD1839 (Ire-
and poor prognosis. Therefore, various members of the ssa, gefitinib), our earlier results raised the issue of
protein kinase family of enzymes have moved into the whether similar resistance formation will also be ob-
focus of intense research efforts aiming at the develop- served for the clinical EGFR inhibitor ZD1839 [5]. More-
ment of target-selective drugs for anticancer therapy over, it remains to be determined whether these known
[2, 3]. Small molecule inhibitors of protein kinases are examples of inhibitor-resistant protein kinases are rep-
resentative of a common theme of drug insensitivity
acquired through substitutions at the conserved site*Correspondence: henrik.daub@axxima.com
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corresponding to Thr-315 of Abl and Thr-766 of the
EGFR.
To address these important questions, we introduced
equivalent amino acid substitutions into three other pro-
tein tyrosine kinases. The sensitivities of the mutant
kinases were determined for a selection of structurally
distinct inhibitors. With one important exception, all of
the inhibitor classes tested were prone to a conserved
mechanism of molecular resistance formation. In addi-
tion, the drug-resistant kinase mutants provided useful
tools for chemical-genetic analysis of cellular signaling.
Results
Protein Kinase Alignment and Inhibitor Selection
The side chain of Thr-315 in the Abl tyrosine kinase
controls the access to a hydrophobic pocket at the ATP
binding site [7, 9]. This cavity accommodates moieties
of ATP-competitive inhibitors, such as STI571 and
PD180970, but no functional groups of ATP itself [9, 13].
Thus, replacement of Thr-315 by larger residues inter-
feres with inhibitor binding, while leaving the kinase ac-
tivity intact. The smaller amino acids threonine or valine
are present at the corresponding site in a subset of all
human kinases, and an alignment of those belonging to
this group and relevant for this study is shown in Figure
1A. For a comprehensive analysis of this structural fea-
ture with respect to resistance formation, we selected
a variety of inhibitors belonging to distinct compound
classes (Figure 1B). The EGFR inhibitor ZD1839 (Iressa,
gefitinib) has recently received FDA approval for third-
line treatment of non-small cell lung cancer [5, 14]. The
pyrazolopyrimidine PP1 was originally described as a
Src family kinase-specific inhibitor but was later found
to block PDGFR activity with similar potency [15]. The
2-phenylaminopyrimidine STI571 is a potent inhibitor
of the tyrosine kinases Abl, c-kit, and PDGFR [6]. The
quinoxaline compound AG1296 is used as a selective Figure 1. Protein Kinase Alignment and Inhibitor Structures
PDGFR inhibitor [16]. The pyrido[2,3-d]pyrimidine-based (A) Residues surrounding Thr-315 in Abl aligned with the corre-
inhibitor used in this study has previously been described sponding sequences of EGFR, PDGFR, Src, and the FGFR1. Thr-
as compound 58 out of a series of pyrido[2,3-d]pyrimi- 315 in Abl and the equivalent amino acids in the other protein kinases
are highlighted in gray.dines by Klutschko et al. and is referred to as PP58 [17].
(B) The chemical structures of ZD1839, PP1, STI571, AG1296, aPP58 is known to block the in vitro activities of PDGFR,
pyrido[2,3-d]pyrimidine-based compound (PP58), and three indoli-fibroblast growth factor receptor (FGFR), and Src tyro-
nones (SU6668, SU6656, SU4984) are shown.sine kinases with nanomolar IC50 values. The indolinone
SU6668 was developed as an angiogenesis inhibitor for
anticancer therapy targeting three receptor tyrosine ki- vanced of these drugs [5]. To analyze potential EGFR
nases (RTKs) involved in this process (PDGFR, FGFR1, resistance formation to ZD1839, we transiently ex-
and vascular endothelial growth factor receptor-2) [18]. pressed both wild-type EGFR and the EGFR-T766M mu-
Finally, the indolinones SU6656 and SU4984 have been tant in CHO-K1 cells, which lack endogenous EGFR
described as inhibitors of Src family kinases and FGFR1, expression. As shown in Figure 2, pretreatment of cells
respectively [19, 20]. with 25 nM ZD1839 strongly suppressed EGF-stimu-
lated tyrosine phosphorylation of the wild-type RTK,
whereas, in stark contrast, 100-fold higher concentra-Substitution of Methionine for Thr-766 Desensitizes
the EGFR to the Anticancer Drug ZD1839 tions were without effect on the EGFR-T766M mutant.
Thus, molecular resistance formation of the EGFR is alsoIn a previous report, we demonstrated that replacing
Thr-766 with methionine dramatically reduced the sensi- observed for ZD1839 upon introduction of the equivalent
nucleotide change that substitutes Thr-315 with isoleu-tivity of the EGFR to inhibition by the specific 4-anilino-
quinazoline PD153035 [12]. Importantly, structurally cine in Bcr-Abl from STI571-insensitive CML patients.
Moreover, in case of the EGFR, the C to T transitionrelated quinazolines have been developed for target-
selective inhibition of the EGFR in human cancer pa- replacing Thr-766 with methionine (ACG to ATG) would
occur within a CpG dinucleotide sequence. Notably, duetients, and ZD1839 (Iressa, gefitinib) is the most ad-
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Figure 2. EGFR-T766M Is Resistant to ZD1839
CHO-K1 cells lacking endogenous EGFR expression were transiently transfected with pLXSN expression plasmids encoding either wild-type
EGFR or the EGFR-T766M mutant. Serum-starved cells were preincubated with the indicated concentrations of ZD1839 or DMSO for 25 min
prior to stimulation with 10 ng/ml EGF for 5 min. After cell lysis and immunoprecipitation, EGFR was analyzed by immunoblotting with anti-
phosphotyrosine (PY) antibody (upper panels). In parallel, the amount of EGFR in immunoprecipitates was detected using anti-EGFR antibody
(lower panels).
to their susceptibility to methylation-deamination reac- conversion leads to dramatic resistance formation of
the PDGFR. This finding extends previous data fromtions, these sites are mutational hotspots within the hu-
man genome and therefore account for the most fre- mutational analysis of this position in the PDGFR.
Bo¨hmer et al. demonstrated STI571 resistance upon re-quent forms of single-nucleotide substitutions [21]. It
remains to be determined whether this particular type placement of Thr-681 with a much bulkier phenylalanine
residue, but this type of substitution is unlikely to occurof mutation indeed occurs in ZD1839-treated patients.
If so, the Thr-766 to methionine mutation in the EGFR in vivo, as it would require a double nucleotide change
in codon 681 of the PDGFR [24]. We then comparedwould be a marker of significant diagnostic value.
the sensitivities of wild-type and mutant receptors to
various other PDGFR tyrosine kinase inhibitors be-Analysis of PDGFR Sensitivity to Different
Protein Kinase Inhibitors upon Replacement longing to different compound classes. These experi-
ments revealed that the Thr-681 to isoleucine mutationof Thr-681 with Isoleucine
Activation of the PDGFR tyrosine kinase has been es- conferred resistance to PP1, AG1296, and the pyrido-
[2,3-d]pyrimidine compound PP58 (Figures 3A–3C).tablished as critical for the progression of various types
of cancers such as glioblastoma, dermatofibrosarcoma Based on these results, PDGFR resistance formation
due to Thr-681 mutation emerges as a rather broadprotuberans, and chronic myelomonocytic leukemia [4].
STI571 (Gleevec) inhibits the PDGFR as potently as concept relevant for a variety of structurally unrelated
PDGFR kinase inhibitors.the Abl tyrosine kinase, and exploratory clinical testing
has already indicated efficacy of STI571 in hyperprolifer- Importantly, we found a notable exception to this rule,
as Thr-681 was not critical for inhibition by the indoli-ative diseases with constitutive PDGFR activation [4,
22, 23]. This raises the important issue of whether clinical none drug SU6668. As seen in Figure 3D, both wild-type
and mutant PDGFR were inhibited by this compoundresistance formation in these PDGFR-driven malignan-
cies might occur through similar mechanisms as demon- with an comparable IC50 of about 0.5 to 1 M in intact
cells.strated for Bcr-Abl in late-phase CML patients. Here, we
focus on the single C to T nucleotide change known to
confer STI571-resistance to Bcr-Abl by replacing Thr-315 Analysis of Resistance Formation for Src
and FGFR1 Tyrosine Kinase Mutantswith isoleucine. Analogous mutation of the equivalent
codon 681 of the PDGFR generated thePDGFR-T681I The PDGFR mutant experiments established Thr-681
as a structural determinant critical for sensitivity to sev-mutant possessing the same amino acid substitution.
We then transiently expressed both wild-type receptor eral distinct inhibitor scaffolds. We next asked whether
these findings can be extended to other tyrosine kinaseand the PDGFR-T681I mutant in COS-7 cells and mea-
sured the effect of STI571 treatment on PDGF-stimu- targets. For this purpose, we replaced the equivalent
amino acids Thr-341 in the cytoplasmic Src tyrosinelated cellular RTK activity by immunoblot analysis of
PDGFR autophosphorylation on intracellular tyrosine kinase and Val-561 in the FGFR1 RTK with larger methio-
nine residues. To activate Src tyrosine kinase, the car-residues. As shown in Figure 3A, ligand-triggered cellu-
lar activity of the wild-type PDGFR was strongly sup- boxy-terminal Tyr-530 residue, which negatively regu-
lates Src upon C-terminal Src kinase (CSK)-mediatedpressed by the 2-phenylaminopyrimidine STI571 with
an IC50 value somewhat below 1 M, whereas inhibitor phosphorylation, was mutated to phenylalanine, and the
resulting Src-Y530F and Src-T341M-Y530F mutantsconcentrations of up to 25 M did not affect the T681I
mutant. Thus, the rather modest threonine to isoleucine were transiently expressed in COS-7 cells [25]. Cellular
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Figure 3. Mutant PDGFR Sensitivity to Different Protein Kinase Inhibitors
COS-7 cells were transiently transfected with empty vector or pLXSN expression plasmids encoding PDGFR or PDGFR-T681I. Serum-
starved cells were preincubated with the indicated inhibitor concentrations of STI571 or AG1296 (A), PP58 (B), PP1 (C), or SU6668 (D) for 30
min prior to stimulation with 30 ng/ml PDGF-B/B for 5 min. After cell lysis, PDGFR was immunoprecipitated and analyzed by immunoblotting
with anti-phosphotyrosine antibody (PY, upper panels). In parallel, expression levels of transiently expressed PDGFR in total cell lysates
were measured with anti-PDGFR antibody (lower panels).
Src kinase activity was then measured by immunoblot tained for the PDGFR and Src tyrosine kinases. Con-
analysis with antiserum specifically recognizing Src- versely, the FGFR-specific indolinone inhibitor SU4984
mediated autophosphorylation on its tyrosine residue inhibited both wild-type FGFR1 and the V561M mutant
419. As seen in Figure 4A, the widely used inhibitor PP1 in a comparable dose-dependent manner with an IC50
suppressed cellular autophosphorylation of activated around 10 M (Figure 4E). Taken together, our data
Src tyrosine kinase with an IC50 value of about 5 M, establish the concept that efficient inhibition by many
whereas full resistance at 25 M PP1 was observed for kinase inhibitors requires a threonine or valine in a con-
the Src variant possessing the Thr-341 to methionine served position at the ATP binding site, where these
mutation. These results are consistent with previous smaller residues sterically control the interaction of in-
in vitro studies by Shokat and colleagues and verify the hibitor moieties with a hydrophobic pocket not involved
in vivo relevance of their earlier findings [26]. When we in binding of ATP itself. But, as verified for three deriva-
tested the pyrido[2,3-d]pyrimidine inhibitor PP58 against tives with three different kinase targets, inhibition by
the activities of either Src-Y530F or Src-T341M-Y530F indolinone compounds occurs independently of this
in intact cells, dramatic resistance formation became structural determinant.
apparent. The T341M mutation abrogated the sensitivity
to PP58 inhibition by increasing the cellular IC50 value
of about 10 nM by more than 1000-fold (Figure 4B). This Cellular Signaling Mediated by Inhibitor-
finding was in stark contrast to results obtained with Insensitive PDGFR Tyrosine Kinase
the Src kinase inhibitor SU6656 [19]. This indolinone
PDGFR tyrosine kinases are expressed in most cell
compound inhibited both Src variants irrespective of a
types. To investigate the signaling capacity of drug-
threonine or methionine residue present at the critical
resistant PDGFR in intact cells, it was either necessaryposition 341 with an cellular IC50 in the range of 3 to to introduce wild-type and mutant receptors into a10 M (Figure 4C). Moreover, we consistently observed
PDGFR-deficient cell system or to specifically triggeran increased phospho-Tyr-419 signal for the Src-
signaling through an ectopically expressed receptorT341M-YF mutant, indicating that substitution of Thr-
without activating its endogenous counterpart. We341 with methionine did not abrogate but instead some-
chose the second strategy and made use of immortal-what enhanced the cellular Src kinase activity (Figures
ized EF1.1/ fibroblasts derived from EGFR knockout4A–4C). A similar observation was made when the cellu-
mice, in which we expressed chimeric RTKs consistinglar autophosphorylation of wild-type FGFR1 was com-
of the extracellular domain of the human EGFR and thepared with mutant receptor, which possessed a methio-
transmembrane and cytoplasmic domains of either wild-nine residue instead of the Val-561 corresponding to the
type (EPR) or T681I mutant PDGFR (EPR-T681I) [27,equally sized Thr-341 of Src (Figures 4D and 4E). The
28]. In these cell lines, intracellular PDGFR signalingcellular wild-type FGFR1 activity was potently inhibited
could then be specifically induced upon extracellularby low nanomolar concentrations of the broadly active
addition of EGF. As shown in Figure 5A, both wild-typepyrido[2,3-d]pyrimidine tyrosine kinase inhibitior PP58,
EPR and the T681I mutant were expressed at compara-whereas dramatic resistance formation was detected
ble levels and became tyrosine phosphorylated to afor the FGFR1-V561M mutant (Figure 4D). Thus, FGFR1
mutant analysis yielded similar results for PP58 as ob- similar extent upon EGF stimulation. Moreover, in accor-
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Figure 4. Cellular Resistance Formation of Src and FGFR1 Tyrosine Kinase Mutants
Control-transfected COS-7 cells or COS-7 cells transiently expressing human Src-Y530F, Src-T341M-Y530F, FGFR1, or FGFR1-V561M were
serum starved for 24 hr. Prior to lysis, cells were treated with the indicated inhibitor concentrations of PP1 (A), PP58 (B and D), SU6656 (C),
or SU4984 (E) for 30 min.
(A–C) Src tyrosine kinase in total lysates was analyzed by parallel immunoblotting with anti-phosphoTyr-419-Src family kinase specific antibody
(upper panels) and anti-v-Src antibody (lower panels).
(D and E) FGFR1 was purified with WGA-Sepharose, and tyrosine-phosphorylated FGFR1 was detected by immunoblotting with anti-phospho-
tyrosine antibody (PY, upper panels). In parallel, the amount of FGFR1 was analyzed using anti-FGFR1 antiserum (lower panels).
dance with the results presented above, 25 M of either nucleotide mutation as previously found in codon 315
of Abl kinase from STI571-resistant CML patients.PP1 or STI571 abrogated wild-type EPR tyrosine phos-
phorylation, but was without effect on the activation of Pharmacological analysis of PDGFR signal transduc-
tion employing the Src family kinase inhibitor PP1 hasthe EPR-T681I mutant. For these two compounds, we
further analyzed the mitogenic responses through wild- always been hampered by the fact that the PDGFR itself
is targeted by this compound. Utilizing the EPR-T681I-type and inhibitor-resistantPDGFR tyrosine kinases on
the levels of mitogen-activated protein kinase (MAPK) expressing fibroblasts, we were now able to conduct
this type of experiment and prepared total lysates fromactivation, c-Fos protein expression, and DNA synthesis
[12]. As shown in the time-course experiment in Figure either wild-type or EPR-T681I-expressing cells after dif-
ferent times of EGF stimulation in the presence or ab-5B, STI571 pretreatment of EPR-expressing cells strongly
interfered with the activation of the extracellular signal- sence of PP1. Surprisingly, although rapid induction of
ERK activity was reconstituted through inhibitor-insen-regulated protein kinase (ERK) MAPKs and c-Fos pro-
tein production upon EGF addition. Protein levels of the sitive PDGFR kinase in the presence of PP1, this com-
pound abrogated the sustained ERK activity observedc-Fos transcription factor were analyzed as a surrogate
marker for c-fos immediate-early gene induction. In con- in control-treated cells as revealed by time-course anal-
ysis (Figure 5B). As further seen in Figure 5B, the lesstrast, neither downstream signaling event was affected
by STI571 when triggered through the STI571-resistant sustained ERK activation also resulted in a strongly re-
duced expression of c-Fos protein upon EPR-T681Iintracellular domain in EPR-T681I-expressing fibro-
blasts. Moreover, ligand-stimulated DNA synthesis was stimulation. As analyzed by anti-phosphotyrosine immu-
noblots of the same lysates, the time course of EPR-only slightly diminished by 25 M STI571 in cells ex-
pressing the inhibitor-insensitive chimeric RTK, whereas T681I phosphorylation appeared to be unaffected by
PP1 pretreatment (data not shown). Thus, PP1 interferedthymidine incorporation induced through wild-type
PDGFR kinase was already reduced to basal levels by with a signaling step downstream of the PDGFR and
upstream of ERK activation. Moreover, these PP1-sensi-5-fold lower STI571 concentrations (Figure 5C). These
results demonstrate that the antiproliferative effect of tive signal transducers are unlikely to be Src family ki-
nases, as previous data have excluded a role for theseSTI571 on PDGFR-mediated signaling is dramatically
reduced upon introduction of the equivalent C to T single kinases in ERK and c-Fos activation and instead impli-
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cated them in PDGFR-mediated c-Myc induction [19].
Therefore, the PP1 effect more likely relates an unrecog-
nized element critically involved in PDGFR signaling.
As measured in thymidine incorporation experiments,
the antiproliferative effect of PP1 was more pronounced
in EPR- than in EPR-T681I-expressing cells (Figure 5C).
From these results, we conclude that the PDGFR itself
is the most sensitive PP1 target required for PDGFR-
mediated cell cycle progression.
A Chemical-Genetic System to Trigger Cellular
Src Kinase Signaling
Src family kinases are negatively regulated through
CSK-mediated phosphorylation of a tyrosine residue at
their C terminus. Therefore, pharmacological inhibition
of CSK activity in intact cells would trigger Src kinase
signaling. The pyrido[2,3-d]pyrimidine tyrosine kinase
inhibitior PP58 is known to be effective against PDGFR,
FGFR, and Src family kinases, and, in addition, related
derivatives potently interfere with Abl tyrosine kinase
activity in the low nanomolar range [10, 17]. Furthermore,
we could identify CSK as a potential target of pyrido[2,3-
d]pyrimidine-based compounds employing a chemical
proteomics approach (H.D. and J. Wissing, unpublished
data). In vitro kinase assays revealed that PP58 inhibited
CSK activity with an IC50 value of around 100 nM (Figure
6A). Based on this result, we assumed that PP58 could
activate Src in intact cells through CSK inhibition in case
Src itself is not targeted by the pyrido[2,3-d]pyrimidine
derivative. Our identification of Thr-341 as the residue
critical for Src inhibition by PP58 allowed us to test this
hypothesis. To verify the model for pharmacological Src
activation shown in Figure 6B, we transiently expressed
either wild-type Src or the inhibitor-insensitive Src-
T341M mutant and then treated the transfected COS-7
with PP58. As shown in Figure 6C, cellular kinase activity
of the PP58-resistant T341M mutant was indeed stimu-
lated within only 5 min of PP58 incubation, as revealed
by immunoblot analysis with antiserum specifically de-
tecting Src autophosphorylation. Prolonged incubation
with PP58 did not further increase Src phosphorylation
on Tyr-419. In contrast, the PP58-sensitive wild-type
kinase was not stimulated, although expressed at similar
levels (Figure 6C). PP58-induced Src-T341M activity led
to the tyrosine phosphorylation of various cellular pro-
teins, and this effect was specific for the transfected
Figure 5. Inhibitor Effects on Cellular Signaling through Drug-Resis- Src mutant since PP58 even reduced the basal tyrosine
tant PDGFR
phosphorylation in control-transfected and wild-type
Control EF1.1/ fibroblasts or cells stably expressing either chime-
Src expressing cells (Figure 6C, lower panel). Theseric EPR or the EPR-T681I mutant were serum-starved for 24 hr.
experiments establish a new chemical-genetic strategy(A) After preincubation with 25 M of either PP1 or STI571 for 30
for small molecule-regulated stimulation of cellular Srcmin where indicated, cells were stimulated for 5 min with 50 ng/ml
EGF prior to lysis. EPR was immunoprecipitated with mAb108.1 and kinase signaling. Importantly, this straightforward ap-
analyzed by immunoblotting with anti-phosphotyrosine antibody proach can be applied to any of the Src family members
(PY) and anti-PDGFR antibody. with minimal experimental efforts, which might be an
(B) Following pretreatment with 25 M STI571, 25 M PP1, or DMSO
advantage over the more complicated, small molecule-for 30 min, cells were stimulated with 50 ng/ml EGF for the indicated
induced Src kinase membrane targeting system re-times prior to lysis. Total cell extracts were immunoblotted with
ported several years ago [29]. In this earlier work, aeither anti-phospho-ERK1/2 antibody or anti-c-Fos antibody.
(C) EF1.1/ fibroblasts were treated with the indicated concentra- membrane-bound FK506 binding protein 12 (FKBP12)
tions of STI571 and PP1 for 30 min prior to stimulation with 50 ng/ml variant recruited coexpressed FKBP12-Src kinase fu-
EGF. After 14 hr, cells were pulse labeled with methyl-[3H]thymidine sion protein upon addition of a small molecule inducer of
for 2 hr, and its incorporation into DNA was measured. The dpm
FKBP12 dimerization, and this membrane translocationvalues shown represent the mean SD for triplicate samples.
event initiated Src kinase signaling. Compared to the
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mechanistic understanding of Src kinase-mediated sig-
nal transduction in intact cells.
Structural Basis for Differential Inhibitor
Sensitivity of Protein Kinase Mutants
To investigate the molecular basis of the differential
inhibitor sensitivities measured for wild-type and mu-
tated kinases, we docked the indolinone compound
SU6656 and the pyrido[2,3-d]pyrimidine derivative PP58
into a Src homology model. Since our experimental data
was obtained with constitutively active human Src, we
decided to generate a model of active Src instead of
using its crystallized inactive kinase structure [33]. The
model was generated on active Lck (Protein Data Base
ID code 3lck), which shows high sequence identity (67%)
to human Src and is crystallized with a resolution of
1.7 A˚ [34].
Docking studies with both inhibitors to either wild-
type or T341M mutant Src correlated with the experi-
mental data. While SU6656 fit into both wild-type and
mutant Src, PP58 could only be accommodated by the
wild-type enzyme (Figure 7A, upper panels and lower
left panel). These results can be explained by the orien-
tations of both inhibitors in the ATP binding site. Both
ligands form the classical H bonds to the hinge region,
identical to those found in other crystal structures of
similar inhibitors, indicating a correct binding mode [13,
18, 20]. SU6656 uses the carbonyl oxygen of Glu-342
and the backbone NH of Met-344 for H bonding and
exclusively occupies the ATP binding pocket. PP58 es-
tablishes two H bonds to both the amide nitrogen and
the carbonyl oxygen of Met-344 and further extends
its 2,6-dichlorophenyl substituent into the hydrophobic
back pocket adjacent to the ATP binding site. In con-
trast, the indolinone SU6656 does not interact with this
hydrophobic cavity. While SU6656 can be accommo-
dated in the model structure of the Src-T341M mutant
Figure 6. Pharmacological Induction of Src Kinase Signaling Em- (Figure 7A, upper right panel), our docking study did not
ploying an Inhibitor-Resistant Mutant suggest any low energy binding mode that PP58 could
(A) Inhibition of CSK activity by PP58 was determined in vitro. Kinase adapt in the mutant binding pocket. Consistent with
activities in the absence of inhibitor were set to 100%, and remaining these results, superimposition of the PP58 conformation
activities at different PP58 concentrations are shown relative to this derived from the wild-type model with the mutant Srcvalue.
structure resulted in a steric clash of the inhibitor with(B) Model for PP58-induced activation of Src-T341M through cellular
the methionine side chain (Figure 7A, lower left panel).inhibition of antagonizing CSK activity.
(C) COS-7 cells were either control transfected with 2 g pLXSN Thus, mutation of Thr-341 to methionine appears to ab-
vector or cotransfected with 1.5 g of vector DNA plus the pLXSN rogate PP58 binding by blocking the access of the inhibi-
expression plasmids encoding for Src or Src-T341M (0.5 g/well tor’s dichlorophenyl group to the hydrophobic back
each). After serum starvation, cells were incubated with 1 M PP58 pocket.for the indicated times prior to lysis. Total cell lysates were subjected
To compare the binding modes of our docked ligandsto immunoblotting with anti-phosphoTyr-419-Src family kinase spe-
with publicly available X-ray structures of similar com-cific antibody, anti-v-Src antibody, and anti-phosphotyrosine (PY)
antibody. pounds, we superimposed both mutation-insensitive
and mutation-sensitive ligands in the protein environ-
ment of the published structure of active Lck (PDB ID
code 3lck). For clarity, only the surface of the Lck nucleo-FKBP12-based dimerization technique, the chemical-
genetic system presented here should more reliably re- tide binding cavity is shown. The indolinone compound
SU6668 overlays nicely with the adenine part of ATP,produce the regulated cellular localization of Src family
kinases, which is known to occur by mechanisms such and both ligands do not occupy the hydrophobic back
pocket. The conformation of SU6668 derived from itsas palmitoylation-dependent partitioning into lipid rafts
and has functional consequences on substrate phos- FGFR cocrystal structure (PDB ID code 1fgi) is very
similar to our docked SU6656 conformation (Figure 7B)phorylation [30–32]. Thus, our approach might be partic-
ularly useful to characterize cellular substrate proteins [18]. In contrast, PP1 (PDB ID code 1qpe) and the PP58
analog PD173955 (PDB ID code 1m52) both target theof Src family members and thereby contribute to a better
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Figure 7. Structural Basis for Differential Inhibitor Sensitivities of Wild-Type and Mutant Kinases
The pictures were generated with WebLabViewer (A) and Insight II (B).
(A) SU6656 was docked into homology models of the activated forms of both wild-type human Src and the Src-T341M mutant (upper panels).
PP58 was docked into wild-type human Src and manually overlaid with the Src-T341M mutant structure (lower panels). The solvent accessible
surface of the critical residue in position 341 is shown in yellow in all panels. In the lower right panel, the surface of PP58 is shown in pink
to visualize the steric clash of PP58 with the Met-341 side chain in the mutant structure.
(B) Ligand conformations derived from various crystal structures were inserted into the ATP binding pocket of Lck (PDB ID code 1qpe). The
indolinone SU6668 (PDB ID code 1fgi; green/CPK) and ATP (PDB code 1qpc; yellow/CPK) are shown on the left. The inhibitors PP1 (PDB ID
code 1qpe; yellow/CPK) and PD173955 (PDB ID code 1m52; green/CPK) are shown on the right. The yellow arrows point to the hydrophobic
pocket, which accommodates moieties of PP1 and PD173955 but is not targeted by ATP and SU6668.
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hydrophobic back pocket [13], further illustrating the of Src leads to sterical clash with the dichlorophenyl
group of the pyrido[2,3-d]pyrimidine PP58, which is ac-structural basis for resistance formation defined for vari-
ous protein kinases in this study. commodated by a hydrophobic pocket at the ATP bind-
ing site in the wild-type enzyme. In contrast, the T341M
substitution did not interfere with SU6656 binding, since
Discussion no moiety of the indolinone extends into the correspond-
ing cavity of human Src according to our model.
Protein kinase targets are prone to molecular resistance Inhibitor resistance cannot only be exploited for signal
formation, which is of high clinical relevance as exempli- transduction analysis, as shown for PDGFR and Src
fied by a variety of mutations found in STI571-insensitive signaling in this study, but also provides insights for
Bcr-Abl from relapsed CML patients [7, 8]. As shown drug development in the protein kinase field. About 75%
for a PDGFR-T681I mutant equivalent to the clinical of all protein kinases possess a larger, hydrophobic resi-
T315I Abl kinase isolate, our results indicate that similar due, such as methionine, leucine, or phenylalanine, in
molecular insensitivity occurs in case of the PDGFR the position equivalent to the threonine or valine resi-
and can further translate into STI571-resistant but still dues present in the kinases we investigated here [36].
PDGFR-driven biological responses such as cell prolif- Thus, compounds from a variety of inhibitor classes, such
eration. With respect to clinical resistance formation, as 4-anilinoquinazolines, pyrazolopyrimidines, 2-phenyl-
these results could become a relevant feature for STI571 aminopyrimidines, quinoxalines, and pyrido[2,3-d]py-
therapy of malignancies, such as dermatofibrosarcoma rimidines, might preferably target only a small subset of
protuberans and chronic myelomonocytic leukemia, in protein kinases possessing a small residue at the critical
which defined chromosomal translocations trigger con- site corresponding to Thr-315 of Abl. In contrast, indoli-
stitutive PDGFR signaling causative for disease pro- nones are not selective according to this criteria, at least
gression [4, 22, 23]. The same conserved threonine not the derivatives we have tested. In addition to drug-
might also be critical for the RTK c-kit, the cellular target resistance studies performed by others and our group,
of STI571 therapy in gastrointestinal stromal tumors, selectivity profiling of PP1 and SU6656 against a panel of
and a recent study indeed detected the corresponding recombinant kinases supports this concept [37]. These
mutation in the tyrosine kinase domain of the PDGFR structural aspects might aid the design of compound
in an STI571-treated patient suffering from idiopathic libraries optimized for the screening of each individual
hypereosinophilic syndrome [4, 35]. In addition, muta- protein kinase target and thereby help to develop more
tions analogous to the Y253F, E255K, M351T, H396P, potent and selective drugs for the treatment of diseases
and a variety of other substitutions in the Abl kinase with unmet medical needs.
domain associated with STI571 resistance in CML might
also affect PDGFR and c-kit sensitivities [7, 8]. This re-
mains to be tested. These amino acid replacements Significance
appear to affect the characteristic inactive conforma-
tion, which Abl has to adopt for high affinity interaction Protein kinases are key control elements of cellular
signaling and therefore represent a major family ofwith STI571. Despite their relevance for STI571 sensitiv-
ity, these mutations did not affect Abl kinase inhibition drug targets. Numerous selective and potent small
molecule inhibitors of protein kinases have been iden-by the pyrido[2,3-d]pyrimidine PD180970 [10, 13]. Thus,
from these data, it appears that the Abl kinase domain tified in recent years. These reagents are useful for
both signal transduction research and therapeutic in-mutations can be divided into two groups: some substi-
tutions of general relevance for protein kinase inhibition, tervention in various diseases. The inhibition of some
protein kinases, such as p38, the EGFR, or Bcr-Abl,such as T315I, which directly interfere with inhibitor in-
teraction, and the larger group of those, which are spe- by target-selective, ATP-competitive compounds was
described to depend on the presence of a small threo-cific for STI571 due to the special conformational state
of its targets required for efficient binding. These consid- nine residue at a specific site near the nucleotide bind-
ing pocket. Substitutions with larger residues ren-erations imply that STI571 would be particularly vulnera-
ble to resistance formation and that this risk can be dered mutant protein kinases insensitive to selective
inhibitors without abrogating kinase activity, and thisminimized with target conformation-independent inhibi-
tors. For these compounds, only the direct interaction type of mutation was also prominent in leukemia pa-
tients who had developed resistance to treatment withsites, such as the residue corresponding to Thr-315 of
Abl and Thr-766 of the EGFR, might be critical for protein the BCR-ABL kinase inhibitor STI571 (Gleevec) [7, 11,
12]. We show a similar mode of cellular resistancekinase inhibition. We have therefore focused on the rele-
vance of this structural feature in the present study [7, formation for the EGFR-selective drug ZD1839 (Iressa).
To characterize whether this structural feature is of12]. The equivalent threonines (or the equally sized va-
line, in case of the FGFR) determined the sensitivities general relevance, we tested mutants of several tyro-
sine kinases possessing larger side chains at the criti-for all inhibitor classes analyzed, with the exception of
the indolinones. The structural basis of these experi- cal site against a selection of structurally diverse small
molecule inhibitors. With the exception of the indoli-mental data could further be illustrated by molecular
modeling studies in which the pyrido[2,3-d]pyrimidine none class of compounds, molecular resistance for-
mation was observed for all inhibitor scaffolds tested.PP58 and the indolinone SU6656 were docked into the
wild-type and T341M mutant Src kinase structures. The These results provide a rationale for the generation of
smaller, focused inhibitor libraries, depending on apresence of a long methionine side chain in position 341
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formed with ProStat in Insight II. All nonglycine amino acids weresmall residue like threonine or a larger one present at
in the allowed regions, and all amide bonds were in trans conforma-the critical position of the protein kinase target to be
tion. The overall rmsd of our active conformation of the human Srcscreened for potent inhibitors. In addition to these
model compared to inactive X-ray structures of Src (PDB ID codes
results relevant for drug development, inhibitor-resis- 2src and 1fmk) is 1.1 A˚. The active site mutation of T341 to M was
tant mutants were introduced into a cellular system generated with the Biopolymer Module within Insight II.
The kinase inhibitors SU6656 and PP58 were docked with Molocthat allows the pharmacological dissection of PDGFR-
into wild-type Src and the Src-T341M mutant [42] (www.moloc.ch).mediated signaling with inhibitors previously not suit-
Docked structures were manually inspected and pictures were gen-able for this approach. By employing an inhibitor
erated with WebLabViewer (www.accelrys.com).targeting both Src tyrosine kinase and its negative
regulator CSK, the expression of a drug-insensitive Acknowledgments
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